Nyxoah S.A.

NasdaqGM NYXH

Nyxoah S.A. Price to Earnings Ratio (P/E) on December 30, 2024: -5.44

Nyxoah S.A. Price to Earnings Ratio (P/E) is -5.44 on December 30, 2024, a -62.09% change year over year. Price to earnings ratio compares the stock price to earnings per share; higher P/E suggests expectations for future earnings growth.

Nyxoah S.A. 52-week high Price to Earnings Ratio (P/E) is -3.15 on January 17, 2024, which is 42.04% above the current Price to Earnings Ratio (P/E).
Nyxoah S.A. 52-week low Price to Earnings Ratio (P/E) is -15.26 on March 18, 2024, which is -180.43% below the current Price to Earnings Ratio (P/E).
Nyxoah S.A. average Price to Earnings Ratio (P/E) for the last 52 weeks is -7.37.

Key data

Date	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield

NasdaqGM: NYXH

Nyxoah S.A.

CEO	Mr. Olivier Taelman
IPO Date	April 28, 2021
Location	Belgium
Headquarters	Rue Edouard Belin 12
Employees	146
Sector	Health Care
Industries Pharmaceuticals Telehealth

Description

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

Key trends

Past 5 years